Holen Sie sich die Stockscreener-App
18.88
0.63%
-0.12
Handel nachbörslich:
18.88
Schlusskurs vom Vortag:
$19.00
Offen:
$18.91
24-Stunden-Volumen:
539.14K
Relative Volume:
1.41
Marktkapitalisierung:
$571.75M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-3.6378
EPS:
-5.19
Netto-Cashflow:
$-121.61M
1W Leistung:
-15.71%
1M Leistung:
-46.03%
6M Leistung:
-24.69%
1J Leistung:
+26.71%
1-Tages-Spanne:
$18.03
$19.24
1-Wochen-Bereich:
$18.03
$22.80
52-Wochen-Spanne:
$13.36
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ANAB | 18.88 | 571.75M | 17.16M | -163.62M | -121.61M | -5.19 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio’s (ANAB) “Outperform” Rating Reiterated at Wedbush - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher - Yahoo Finance
JPMorgan Chase & Co. Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
(ANAB) Proactive Strategies - Stock Traders Daily
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) - MSN
Leerink Partnrs Lifts Earnings Estimates for AnaptysBio - Defense World
What is Wedbush’s Forecast for AnaptysBio FY2024 Earnings? - Defense World
FY2024 EPS Estimates for AnaptysBio Lifted by HC Wainwright - Defense World
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? - MSN
What is Wedbush's Forecast for AnaptysBio FY2024 Earnings? - MarketBeat
HC Wainwright Has Lowered Expectations for AnaptysBio (NASDAQ:ANAB) Stock Price - Defense World
AnaptysBio (NASDAQ:ANAB) Earns “Outperform” Rating from Wedbush - Defense World
Lilly bid wilts as others forge on with PD-1 in RA - BioWorld Online
AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet - Simply Wall St
AnaptysBio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - Defense World
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates - MSN
AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Earnings Beat - MarketBeat
AnaptysBio shares hold Outperform rating; Leerink notes strong cash position and clinical progress - Investing.com UK
AnaptysBio stock target cut on increased expenses By Investing.com - Investing.com Canada
AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright - StreetInsider.com
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners - StreetInsider.com
AnaptysBio Inc (ANAB) Q3 2024 Earnings: Revenue Soars to $30M, E - GuruFocus.com
AnaptysBio Reports Q3 2024 Financial Results and Updates - TipRanks
AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c - StreetInsider.com
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Anaptys Announces Participation in November and December Investor Conferences - The Manila Times
AnaptysBio's Q3 Revenue Surges to $30M, Cash Position Hits $458M Ahead of Key Trial Data | ANAB Stock News - StockTitan
AnaptysBio CEO to Present at 4 Major Healthcare Conferences Through Year-End | ANAB Stock News - StockTitan
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4%Here's What Happened - MarketBeat
Things To Consider Before Buying AnaptysBio Inc (NASDAQ: ANAB) - Stocks Register
AnaptysBio: Too Risky, Especially After LLY Drops Its Related Programs - Seeking Alpha
AnaptysBio (ANAB) Shares Plunge as Eli Lilly Ends Arthritis Drug Research - GuruFocus.com
AnaptysBio (NASDAQ:ANAB) Given "Buy" Rating at HC Wainwright - MarketBeat
(ANAB) Trading Advice - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Shares Gap DownHere's What Happened - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $33.00 - MarketBeat
AnaptysBio plunges as Eli Lilly drops co's arthritis drug from pipeline - XM
AnaptysBio stock falls as Lilly updates pipeline (ANAB:NASDAQ) - Seeking Alpha
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - TradingView
Assenagon Asset Management S.A. Grows Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Down 6.9%Here's Why - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus Price Target from Analysts - MarketBeat
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 - Defense World
nVerses Capital LLC Buys 1,400 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Guggenheim reiterates buy rating on AnaptysBio stock, sees favorable risk/reward ahead of December readout - Investing.com Canada
A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts - Benzinga
AnaptysBio (NASDAQ:ANAB) PT Raised to $90.00 at Guggenheim - MarketBeat
(ANAB) On The My Stocks Page - Stock Traders Daily
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):